leisure time -WSS

leisure time

author：knowledge 2025-09-27 18:53:52 - browse：954

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： GSK Flovent asthma inhalers replaced by authorized generics

explore

WSS

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

Princess Kate attends Wimbledon with Roger Federer: See the photos

Antibiotic resistance and the global rise in human conflict

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

leisure time

leisure time

The next ALS data readout — overdue but important

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Search warrant issued in 1996 disappearance of Kristin Smart

Trump demands the U.S. pay no more for drugs than other countries … again

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Walensky prepares to leave CDC — and Congress — behind

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Peter Hotez and the public health issue of online harassment

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Search warrant issued in 1996 disappearance of Kristin Smart

focus

EU moves toward latest gene techniques in food production to counter climate change, shortages

Feng Zhang CRISPR delivery startup lays off quarter of staff

Ahead of JPM, here's who's profiting most in health care

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Condition critical? Britain's beloved but battered National Health Service turns 75

AdventHealth escalates lawsuit against insurance vendor Multiplan

focus

hotspot

explore

hotspot